Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Epix jumps on AD data

EPIX gained $1.05 (35%) to $4.02 on 15.5

Read the full 83 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE